Cutaneous findings associated with chronic natural killer cell lymphocytosis

International Journal of Dermatology

Volumn 41, Issue 12, 2002, Pages 852-857

  Vanness, Erin R ^a   Davis, Mark D P ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DOXEPIN; IMMUNOGLOBULIN; PENTOXIFYLLINE; PREDNISONE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANAMNESIS; APHTHOUS STOMATITIS; BLOOD SMEAR; BONE MARROW BIOPSY; CHRONIC DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOPENIA; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; INSTITUTIONAL CARE; LARGE GRANULAR LYMPHOCYTE; LEG ULCER; LIVEDO RETICULARIS; LYMPHOCYTOSIS; MALE; MEDICAL RECORD; NATURAL KILLER CELL LYMPHOCYTOSIS; PATIENT MONITORING; PATIENT REFERRAL; PERIPHERAL CIRCULATION; PERIPHERAL T CELL LYMPHOMA; RECURRENT DISEASE; RETROSPECTIVE STUDY; SKIN DISEASE; SKIN SCAR; SYSTEMIC DISEASE; THROMBOCYTE COUNT; URTICARIA; VASCULAR DISEASE; VASCULITIS;

ADULT; AGED; CHRONIC DISEASE; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTOSIS; MALE; MIDDLE AGED; SKIN DISEASES;

EID: 0036938237     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2002.01671.x     Document Type: Conference Paper

References (21)

1. Lee GR, Foerster J, Lukens J, et al. Wintrobe's Clinical Hematology, 10th edn, Vol. 1. Baltimore: William & Wilkins, 1999: 525-531.
2. Tefferi A. Chronic natural killer cell lymphocytosis. Leuk Lymphoma 1996; 20: 245-248.
3. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
4. Scott CS, Richards SJ, Sivakumaran M, et al. Transient and persistent expansions of large granular lymphocytes (LGL) and NK-associated (NKa) cells: The Yorkshire Leukaemia Group study. Br J Haematol 1993; 83: 504-515.
5. Sivakumaran M, Richards SJ, Scott CS. Clinical and laboratory characteristics of chronic natural killer cell lymphocytosis. Blood 1996; 87: 1659-1660.
6. - lymphoproliferative disease of granular lymphocytes. Blood 1993; 81: 2363-2368.
7. Tefferi A, Greipp PR, Leibson PJ, Thibodeau SN. Demonstration of clonality, by X-linked DNA analysis, in chronic natural killer cell lymphocytosis and successful therapy with oral cyclophosphamide. Leukemia 1992; 6: 477-480.
8. Tefferi A, Li CY, Witzig TE, et al. Chronic natural killer cell lymphocytosis: A descriptive clinical study. Blood 1994; 84: 2721-2725.
9. Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 1999; 106: 960-966.
10. Klein KL, Pittelkow MR. Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc 1992; 67: 923-933.
11. Tefferi A, Windebank KP, Veeder MH, Kiely JM. Steroid-responsive pure red cell aplasia associated with natural killer cell lymphocytosis. Am J Hematol 1989; 31: 211-212.
12. Jorizzo JL. Livedoid vasculopathy: What is it? Arch Dermatol 1998; 134: 491-493.
13. McCalmont CS, McCalmont TH, Jorizzo JL, et al. Livedo vasculitis: Vasculitis or thrombotic vasculopathy? Clin Exp Dermatol 1992; 17: 4-8.
14. Papi M, Didona B, De Pita O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: Cytokine and platelet P-selectin studies. Arch Dermatol 1998; 134: 447-452.
15. Milstone LM, Braverman IM, Lucky P, Fleckman P. Classification and therapy of atrophie blanche. Arch Dermatol 1983; 119: 963-969.
16. Domzig W, StadlerBM, Herberman RB. Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol 1983; 130: 1970-1973.
17. Kabelitz D, Kirchner H, Armerding D, Wagner H. Recombinant interleukin 2 rapidly augments human natural killer cell activity. Cell Immunol 1985; 93: 38-45.
18. Phillips JH, Gemlo BT, Myers WW, et al. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 1987; 5: 1933-1941.
19. Armant M, Delespesse G, Sarfati M. IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology 1995; 85: 331-337.
20. Asadullah K, Friedrich M, Docke WD, et al. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma. J Invest Dermatol 1997; 108: 743-747.
21. Sun A, Chu CT, Wu YC, Yuan JH. Mechanisms of depressed natural killer cell activity in recurrent aphthous ulcers. Clin Immunol Immunopathol 1991; 60: 83-92.